OBJECTIVE:β-alanine (BA) is a nonproteogenic amino acid that combines with histidine to form carnosine. The amount taken orally in individual doses, however, is limited due to symptoms of paresthesia that are associated with higher doses. The use of a sustained-release formulation has been reported to reduce the symptoms of paresthesia, suggesting that a greater daily dose may be possible. The purpose of the present study was to determine whether increasing the daily dose of BA can result in a similar increase in muscle carnosine in a reduced time. METHODS:Eighteen men and twelve women were randomized into either a placebo (PLC), 6-g BA (6G), or 12-g BA (12G) groups. PLC and 6G were supplemented for 4 weeks, while 12G was supplemented for 2 weeks. A resting blood draw and muscle biopsy were obtained prior to (PRE) and following (POST) supplementation. Plasma and muscle metabolites were measured by high-performance liquid chromatography. The loss in peak torque (ΔPT) was calculated from maximal isometric contractions before and after 250 isokinetic kicks at 180°·sec-1 PRE and POST. RESULTS: Both 12G (p = 0.026) and 6G (p = 0.004) increased muscle carnosine compared to PLC. Plasma histidine was decreased from PRE to POST in 12G compared to PLC (p = 0.002) and 6G (p = 0.001), but no group x time interaction (p = 0.662) was observed for muscle histidine. No differences were observed for any hematological measure (e.g., complete blood counts) or in symptoms of paresthesia among the groups. Although no interaction was noted in ΔPT, a trend (p = 0.073) was observed. CONCLUSION: Results of this investigation indicate that a BA supplementation protocol of 12 g/d-1, using a sustained-release formulation, can accelerate the increase in carnosine content in skeletal muscle while attenuating paresthesia.
RCT Entities:
OBJECTIVE: β-alanine (BA) is a nonproteogenic amino acid that combines with histidine to form carnosine. The amount taken orally in individual doses, however, is limited due to symptoms of paresthesia that are associated with higher doses. The use of a sustained-release formulation has been reported to reduce the symptoms of paresthesia, suggesting that a greater daily dose may be possible. The purpose of the present study was to determine whether increasing the daily dose of BA can result in a similar increase in muscle carnosine in a reduced time. METHODS: Eighteen men and twelve women were randomized into either a placebo (PLC), 6-g BA (6G), or 12-g BA (12G) groups. PLC and 6G were supplemented for 4 weeks, while 12G was supplemented for 2 weeks. A resting blood draw and muscle biopsy were obtained prior to (PRE) and following (POST) supplementation. Plasma and muscle metabolites were measured by high-performance liquid chromatography. The loss in peak torque (ΔPT) was calculated from maximal isometric contractions before and after 250 isokinetic kicks at 180°·sec-1 PRE and POST. RESULTS: Both 12G (p = 0.026) and 6G (p = 0.004) increased muscle carnosine compared to PLC. Plasma histidine was decreased from PRE to POST in 12G compared to PLC (p = 0.002) and 6G (p = 0.001), but no group x time interaction (p = 0.662) was observed for muscle histidine. No differences were observed for any hematological measure (e.g., complete blood counts) or in symptoms of paresthesia among the groups. Although no interaction was noted in ΔPT, a trend (p = 0.073) was observed. CONCLUSION: Results of this investigation indicate that a BA supplementation protocol of 12 g/d-1, using a sustained-release formulation, can accelerate the increase in carnosine content in skeletal muscle while attenuating paresthesia.
Authors: Chad M Kerksick; Colin D Wilborn; Michael D Roberts; Abbie Smith-Ryan; Susan M Kleiner; Ralf Jäger; Rick Collins; Mathew Cooke; Jaci N Davis; Elfego Galvan; Mike Greenwood; Lonnie M Lowery; Robert Wildman; Jose Antonio; Richard B Kreider Journal: J Int Soc Sports Nutr Date: 2018-08-01 Impact factor: 5.150
Authors: Bryan Saunders; Mariana Franchi; Luana Farias de Oliveira; Vinicius da Eira Silva; Rafael Pires da Silva; Vitor de Salles Painelli; Luiz Augusto Riani Costa; Craig Sale; Roger Charles Harris; Hamilton Roschel; Guilherme Giannini Artioli; Bruno Gualano Journal: Eur J Nutr Date: 2018-12-14 Impact factor: 5.614
Authors: Alyssa N Varanoske; Adam J Wells; Gregory J Kozlowski; Yftach Gepner; Cheyanne L Frosti; David Boffey; Nicholas A Coker; Idan Harat; Jay R Hoffman Journal: Physiol Rep Date: 2018-12
Authors: Jan Stautemas; Alexia Van de Loock; Thibaux Van der Stede; Lauren Pringels; Wim Derave Journal: Nutrients Date: 2019-11-23 Impact factor: 5.717
Authors: Alyssa N Varanoske; Jay R Hoffman; David D Church; Ran Wang; Kayla M Baker; Sarah J Dodd; Nicholas A Coker; Leonardo P Oliveira; Virgil L Dawson; David H Fukuda; Jeffrey R Stout Journal: Nutrients Date: 2017-09-07 Impact factor: 5.717
Authors: Pedro Perim; Felipe Miguel Marticorena; Felipe Ribeiro; Gabriel Barreto; Nathan Gobbi; Chad Kerksick; Eimear Dolan; Bryan Saunders Journal: Front Nutr Date: 2019-08-27
Authors: Joseph J Matthews; Eimear Dolan; Paul A Swinton; Lívia Santos; Guilherme G Artioli; Mark D Turner; Kirsty J Elliott-Sale; Craig Sale Journal: Adv Nutr Date: 2021-12-01 Impact factor: 8.701